StreetInsider.com News Articles

Form 4 Quanterix Corp For: Aug 19 Filed by: Elliott Jeffrey Thomas

Thu, 20 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26957035.html

Form 4 Quanterix Corp For: Aug 19 Filed by: Elliott Jeffrey Thomas

Thu, 20 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26957035.html

Form 4 Quanterix Corp For: Aug 17 Filed by: DONNELLY WILLIAM P

Wed, 19 Aug 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260819/26946926.html

Form 4 Quanterix Corp For: Aug 17 Filed by: DONNELLY WILLIAM P

Wed, 19 Aug 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260819/26946926.html

Form 3 Quanterix Corp For: Aug 17 Filed by: Gute James Edward Jr.

Wed, 19 Aug 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260819/26946928.html

Form 3 Quanterix Corp For: Aug 17 Filed by: Gute James Edward Jr.

Wed, 19 Aug 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260819/26946928.html

Form 4 Quanterix Corp For: Aug 15 Filed by: Miller Michael Francis

Mon, 17 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260817/26938113.html

Form 4 Quanterix Corp For: Aug 15 Filed by: Miller Michael Francis

Mon, 17 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260817/26938113.html

Quanterix Corp. (QTRX) PT Lowered to $3 at Canaccord

Mon, 17 Aug 2026 07:05:51 -0400

(Updated - August 17, 2026 7:05 AM EDT)

Canaccord analyst Kyle Mikson lowered the price target on Quanterix Corp. (NASDAQ: QTRX) to $3.00 (from $4.00) while maintaining a Hold rating.

The analyst commented: "We reiterate our HOLD rating on Quanterix (QTRX) shares and lower our price target to $3 from $4. Our price target change is driven by lower base-year estimates after 2Q26 earnings. Before the market open on Monday, August 10, QTRX reported 2Q26 results that were below our estimates and FactSet consensus, reflecting commercial execution challenges and continued softness in academic, government, and pharma end markets. In response, management noted

Quanterix Corp. (QTRX) PT Lowered to $3 at Canaccord

Mon, 17 Aug 2026 07:05:51 -0400

(Updated - August 17, 2026 7:05 AM EDT)

Canaccord analyst Kyle Mikson lowered the price target on Quanterix Corp. (NASDAQ: QTRX) to $3.00 (from $4.00) while maintaining a Hold rating.

Form 4 Quanterix Corp For: Aug 12 Filed by: DONNELLY WILLIAM P

Fri, 14 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26929971.html

Form 4 Quanterix Corp For: Aug 12 Filed by: DONNELLY WILLIAM P

Fri, 14 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26929971.html

Form SCHEDULE 13G/A Quanterix Corp Filed by: Portolan Capital Management, LLC

Fri, 14 Aug 2026 15:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26929373.html

Form SCHEDULE 13G/A Quanterix Corp Filed by: Portolan Capital Management, LLC

Fri, 14 Aug 2026 15:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26929373.html

Quanterix Corp. (QTRX) PT Lowered to $3 at TD Cowen

Tue, 11 Aug 2026 08:04:53 -0400

TD Cowen analyst Dan Brennan lowered the price target on Quanterix Corp. (NASDAQ: QTRX) to $3.00 (from $4.00) while maintaining a Hold rating.

Form 10-Q Quanterix Corp For: Jun 30

Mon, 10 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260810/26895036.html

Form 10-Q Quanterix Corp For: Jun 30

Mon, 10 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260810/26895036.html

Form 8-K Quanterix Corp For: Aug 10

Mon, 10 Aug 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260810/26894822.html

Form 8-K Quanterix Corp For: Aug 10

Mon, 10 Aug 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260810/26894822.html

Quanterix names Jim Gute as chief commercial officer

Mon, 10 Aug 2026 08:01:53 -0400

Quanterix Corporation (Nasdaq: QTRX) has appointed Jim Gute as chief commercial officer, according to a company statement. Gute brings approximately 20 years of senior commercial leadership experience in healthcare and information technology.

Gute most recently served as Senior Vice President and Commercial Manager, General Screening, at Exact Sciences, a company with nearly $3 billion in revenue prior to its acquisition by Abbott Labs in early 2026. Before that, he spent 18 years at GE Healthcare, ultimately serving as President of GE Healthcare after holding a series of progressively senior roles. He holds bachelor's and master's degrees from Cleveland State University and

Quanterix names Jim Gute as chief commercial officer

Mon, 10 Aug 2026 08:01:53 -0400

Quanterix names Jim Gute as chief commercial officer

Mon, 10 Aug 2026 08:01:53 -0400

Quanterix names Jim Gute as chief commercial officer

Mon, 10 Aug 2026 08:01:53 -0400

Quanterix Names Jim Gute Chief Commercial Officer

Mon, 10 Aug 2026 08:01:00 -0400

Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company’s commercial operations.

“We are thrilled to attract commercial leadership of Jim’s caliber to Quanterix, at a pivotal time, ahead of our expansion in diagnostics and with renewed focus on growing our core business,” said Everett Cunningham, President

Quanterix Names Jim Gute Chief Commercial Officer

Mon, 10 Aug 2026 08:01:00 -0400

Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences